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mation. Differences between study out-
comes based on participant’s VO2peak
(18 ml/kg/min versus18 ml/kg/min)
is presented in Table 1. In general,
higher cardiorespiratory fitness was as-
sociated with more favorable clinic pro-
file, lower systemic inflammation, and
reduced fatigue.
The present results confirm that
lung carcinogenesis is associated with el-
evated levels of systemic inflammatory
markers such as TNF-, adhesion mole-
cules (ICAM-1), and acute phase pro-
teins—CRP and IL-6. This is of clinical
importance because these markers have
been shown to play pivotal roles in lung
carcinogenesis and in the pathogenesis of
related disorders such as cancer-related
anorexia and cachexia syndrome.4,5 The
prognostic value of these markers is not
currently known. Elevated levels of sev-
eral systemic inflammatory markers were
also associated with weight loss, higher
fatigue, and lower VO2peak. Of note, even
though PS was 70 for all participants,
VO2peak was, on average, 33% below age-
sex predicted norms. This is the first report
of low aerobic capacity using cardiopul-
monary exercise test, which is considered
the standard procedure assessment of car-
diorespiratory fitness. Low VO2peak has
been recognized as a strong, independent
predictor of cardiovascular mortality and
all-cause mortality in both diseased and
healthy populations. Higher VO2peak was
associated with more favorable clinic pro-
file, lower systemic inflammation, and re-
duced fatigue. As such, low VO2peak may
have significant implications for outcome
and management of NSCLC and studies
further exploring the utility of objective
measures of physical functioning appear
warranted.
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Factors Contributing to
Adjuvant Therapy
Decisions
To the Editor:
With recent randomized trials
showing an absolute survival benefit at
5 years of 8 to 15% with adjuvant
chemotherapy after complete resection
of early stage non–small-cell lung can-
cer (NSCLC),1,2 there has been rapid
uptake of adjuvant therapy as a new
standard in NSCLC in the oncology
community. But despite a significant
increase in prescribing practices of on-
cologists,3,4 as many as 50% of pa-
tients still decline potentially curative
adjuvant chemotherapy for lung can-
cer, in contrast to the high uptake of
adjuvant therapy by patients with breast
and colorectal cancer for a smaller ab-
solute survival benefit.
That lung cancer patients tend to be
older, have more comorbid illnesses,
lower socioeconomic status, and are pre-
dominantly male may all impact on this
difference. Platinum-based treatment may
be perceived as more toxic, and older lung
cancer patients are less willing to accept
even low levels of treatment-related tox-
icity.5 But are there additional barriers to
accepting adjuvant chemotherapy for pa-
tients with resected NSCLC?
Understanding elements of the pa-
tient decision-making process may iden-
tify barriers responsible for treatment re-
fusal that, once removed, could lead to
improved health outcomes for this patient
population. To elicit factors contributing
to patient decision-making regarding ad-
juvant therapy, we conducted semistruc-
tured interviews with patients following
resection of early stage NSCLC, including
those who had declined treatment.
Patients were most likely to use
their medical oncologist and surgeon as
information resources during the decision-
making process, with family members and
family practitioners also playing an impor-
tant role. Those who declined treatment
reported greater reliance on family as an
information resource, and used a narrower
spectrum of resources (e.g., brochures,
hospital classes, news magazines), com-
pared with those who accepted treatment.
Also, prior experience with chemotherapy
differed between the groups. Those who
declined treatment had less experience
with chemotherapy through friends and
family, but reported negative experiences.
Those who declined therapy were primar-
ily concerned with the potential for severe
consequences (e.g., prolonged duration of
feeling unwell, loss of independence, and
poor quality of life in remaining years of
advanced age). Those who accepted che-
motherapy were more likely to have had
exposure to chemotherapy experiences
through friends and family, but did not
report negative experiences.
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All patients reported confidence
with the advice given and completeness
of information received, and felt their
concerns were addressed. Individuals in
both groups sought other opinions, most
commonly from their family practitio-
ner. Those that declined adjuvant ther-
apy frequently commented on perceived
support from healthcare professionals
and family, suggesting that lack of sup-
port during decision-making was not a
barrier to accepting treatment. It might
also suggest that those who choose op-
tions other than the oncologists’ recom-
mendation feel a greater need to justify
their decision. Finally, despite available
data from randomized trials, few pa-
tients in either group recalled being pro-
vided with survival statistics from clin-
ical trials during their decision-making
process, but most were satisfied with the
process.
Based on our initial findings, it
seems that patients who decline adju-
vant therapy tend to access fewer infor-
mation resources in the decision-making
process, and focus on the potential for
severe toxicity and negative outcomes.
Thus, better education strategies should
be considered for some patients, and
information and decision support should
be tailored to meet the needs and values
of the individual. A number of decision
aids are under development for this
group, and may improve decision-mak-
ing regarding adjuvant therapy for lung
cancer.
Kathryn L. Howe, PhD
Department of Medical
Oncology/Hematology
Princess Margaret Hospital/University
Health Network
Undergraduate Medicine Program
Faculty of Medicine
Natasha B. Leighl, MD, MMSc
FRCPC
Department of Medical
Oncology/Hematology
Princess Margaret Hospital/University
Health Network
University of Toronto, Canada
natasha.leighl@uhn.on.ca
REFERENCES
1. Winton TL, Livingston R, Johnson D, et al.
National Cancer Institute of Canada Clinical
Trials Group; National Cancer Institute of the
United States Intergroup JBR. 10 Trial Inves-
tigations. Vinorelbine plus cisplatin vs. obser-
vation in resected non-small cell lung cancer.
NEJM 2005;352:2589–2597.
2. Douillard J, Rosell M, Delena M, et al. Adju-
vant vinorelbine plus cisplatin versus obser-
vation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer (Ad-
juvant Navelbine International Trialist Asso-
ciation [ANITA]): a randomised controlled
trial. Lancet Oncol 2006;7:719–727.
3. Kassam F, Shepherd F, Johnston M, et al.
Referral patterns for adjuvant chemotherapy
in patients with completely resected non-
small cell lung cancer. J Thorac Oncol 2007;2:
39–43.
4. Milleron B, Debrix I, Gounand V, Wislez M.
Impact of randomized clinical trials on clini-
cal practice regarding treatment of lung can-
cer. J Thorac Oncol 2007;2:456.
5. Pepe C, Hasan B, Winton TL, et al. Adjuvant
vinorelbine and cisplatin in elderly patients:
National Cancer Institute of Canada and In-
tergroup Study JBR. 10. J Clin Oncol
2007;25:1553–1561.
Immune Hemolytic
Anemia After
Treatment with
Pemetrexed for Lung
Cancer
To the Editor:
Pemetrexed is a structurally novel
antifolate agent. Unlike the “classic” an-
timetabolite drugs including methotrex-
ate and fluorouracil which target a single
enzyme, pemetrexate and its polygluta-
mated forms inhibit enzymes that re-
quire folate, such as dihydrofolate re-
ductase, thymidylate synthase, and
glycinamide ribonucleotide formyl-
transferase.1 The United States Food
and Drug Administration has approved
pemetrexed in combination with cispla-
tin for the treatment of patients with
malignant pleural mesothelioma. Pem-
etrexed has also been approved for use
as a single agent for previously treated
patients with locally advanced or meta-
static non-small cell lung cancer on
2004.2 Although several drug-related
deaths with severe hematologic toxicity
were seen in the early trials of pem-
etrexed, they were overcome by supple-
mentation of folate and vitamin B12. In
the phase III trials that led to the drug’s
approval, immune hemolytic anemia
(IHA) was never reported in patients
receiving pemetrexed alone or in com-
bination with cisplatin.
A 62-year-old man was admitted
for evaluation of a newly developed
neck mass. The chest computed tomog-
raphy scan showed 6-cm-sized lung
mass in the right upper lobe and meta-
static nodules in the left lower lobe.
Adenocarcinoma was diagnosed by
means of excisional biopsy of the neck
mass. Despite several chemotherapy tri-
als using different regimens such as pac-
litaxel plus cisplatin and gefitinib, the
patient’s lung cancer continuously pro-
gressed. As a final salvage chemother-
apy regimen, pemetrexed was given to-
gether with vitamin supplementation.
The baseline hemoglobin, lactate dehy-
drogenase, and total bilirubin were 97
g/l (130–170 g/l), 451 IU/l (240–480
IU/l), and 0.2 mg/dl (0.2–1.3 mg/dl),
respectively. After 20 days, the hemo-
globin level suddenly dropped to 43 g/l
without any evidence of bleeding on
endoscopy, stool occult blood test, and
urine analysis. The white blood cell
count and platelet count were normal.
There were no deficiencies of iron, fo-
late, and vitamin B12. The serum lactate
dehydrogenase was elevated to 711 IU/l
and the total bilirubin was 1.8 mg/dl
without a detectable level of conjugated
form. The reticulocyte production index
was increased to 2.74. Anistocytosis,
poikilocytosis, and polychromasia with
numerous nucleated red blood cells
(RBCs) were found on peripheral blood
smear, suggesting hemolytic anemia
(Figure 1). The results of direct anti-
globulin test performed by tube and gel
microcolumn assay were positive with
only anti-C3d (1). In the drug in vitro
tests, agglutination was observed at
37°C (1) only when the patient’s se-
rum sample was mixed with enzyme-
treated red cells in the presence of pem-
etrexed. Taken together, we detected an
antibody to pemetrexed which appeared to
be the likely cause of the patient’s IHA.
As for treatment, transfusion of packed
RBCs was done together with indefinite
cessation of pemetrexed. The patient’s he-
moglobin level normalized and was sus-
tained without any steroid therapy.
Many drugs, including chemothera-
peutic agents, are known to cause drug-
induced IHA. Methotrexate, a dihydrofo-
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